GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmala Biotech Holdings Inc (XCNQ:MDMA) » Definitions » Research & Development

Pharmala Biotech Holdings (XCNQ:MDMA) Research & Development : C$0.07 Mil (TTM As of Nov. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Pharmala Biotech Holdings Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Pharmala Biotech Holdings's Research & Development for the three months ended in Nov. 2024 was C$0.03 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Nov. 2024 was C$0.07 Mil.

Pharmala Biotech Holdings Research & Development Historical Data

The historical data trend for Pharmala Biotech Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmala Biotech Holdings Research & Development Chart

Pharmala Biotech Holdings Annual Data
Trend Aug21 Aug22 Aug23 Aug24
Research & Development
- - -0.17 0.13

Pharmala Biotech Holdings Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 Aug24 Nov24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.04 0.03 - 0.03

Pharmala Biotech Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Nov. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.07 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmala Biotech Holdings  (XCNQ:MDMA) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Pharmala Biotech Holdings Research & Development Related Terms

Thank you for viewing the detailed overview of Pharmala Biotech Holdings's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharmala Biotech Holdings Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmala Biotech Holdings Inc (XCNQ:MDMA) » Definitions » Research & Development
Comparable Companies
TSXV:SBM TSXV:KNE XCNQ:TELI TSX:CSCI XCNQ:PREV TSXV:HEM XCNQ:BETR XCNQ:PHRM XCNQ:BIOV TSX:RVX VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
MDXXF:USA
Address
1 Adelaide Street East, Suite 801, Toranto, ON, CAN, M5C 2V9
Website
https://www.pharmala.ca
Pharmala Biotech Holdings Inc is focused on manufacturing and sales of MDMA and MDXX Active Pharmaceutical Ingredients (API) for use in clinical research. Its drug API is manufactured and encapsulated under GMP conditions. The company generates revenue from the sale of tablets and raw MDMA and MDXX compounds/formulations and royalties from licensing of its IP.
Executives
Fraser Macdonald Director
Perry Tsergas Director
Shane H.d. Morris Director, Senior Officer
Nicholas Kadysh Director, Senior Officer

Pharmala Biotech Holdings Headlines

No Headlines